Shanghai InnoStar Bio-tech Co., Ltd. (SHA:688710)
China · Delayed Price · Currency is CNY 56.80
-1.80 (-3.07%)
At close: Feb 2, 2026
SHA:688710 Revenue
Shanghai InnoStar Bio-tech had revenue of 195.46M CNY in the quarter ending September 30, 2025, a decrease of -29.39%. This brings the company's revenue in the last twelve months to 829.92M, down -26.03% year-over-year. In the year 2024, Shanghai InnoStar Bio-tech had annual revenue of 1.14B with 9.94% growth.
Revenue (ttm)
829.92M
Revenue Growth
-26.03%
P/S Ratio
9.65
Revenue / Employee
764.91K
Employees
1,092
Market Cap
8.01B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.14B | 103.24M | 9.94% |
| Dec 31, 2023 | 1.04B | 175.36M | 20.32% |
| Dec 31, 2022 | 863.07M | 281.30M | 48.35% |
| Dec 31, 2021 | 581.77M | 248.00M | 74.30% |
| Dec 31, 2020 | 333.77M | 89.01M | 36.36% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Nanjing Pharmaceutical Group Company | 53.89B |
| Zhejiang Int'l Group | 33.54B |
| Yifan Pharmaceutical | 5.22B |
| Zhejiang Jolly Pharmaceutical Co.,LTD | 2.81B |
| GuangYuYuan Chinese Herbal Medicine | 1.39B |
| Zhejiang Wolwo Bio-Pharmaceutical | 1.05B |
| Chongqing Lummy Pharmaceutical | 771.02M |
| Hangzhou Minsheng Healthcare | 744.06M |